Biomarin Pharmaceutical 주식 (NASDAQ: BMRN)

에 대한 최신 뉴스 Biomarin Pharmaceutical (NASDAQ:BMRN) 주식

Biomarin Pharmaceutical

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Large Cap

News

Movers

Trading Ideas

ASND

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

New Oriental Education & Technology Group

MUFG

NICE

지난주 이들 10개 대형주는 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 나이스(NASDAQ:NICE)의 주가는 회사가 1분기 재무 결과를 보고하고 2분기 조정 매출 지침을 예상치보다 낮은 수준으로 발표한 후 15.60% 하락했다.

리 오토는 지난주 최악의 성과를 보인 10개의 대형주 중 하나 (5월 12일-5월 18일)

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical Inc

Last week, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">disproportionate short stature</a>.
Goldman Sachs hosted an investor meeting with BioMarin Pharmaceutical Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) Alexander Hardy (President and CEO) and Brian Mueller (EVP, CFO).
They reiterated financial guidance after reviewing their assumptions around Voxzogo competition post-Ascendis Pharma's better-than-expected Phase 3 achondroplasia data.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40200109/rare-disease-focused-biomarin-narrows-sales-focus-cuts-cost-for-hemophilia-a-gene-t" rel="noreferrer noopener">Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance</a>.
The analyst notes that management believes a U.S./EU launch by Ascendis Pharma could violate its C-type natriuretic <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40885653/despite-being-first-mover-biomarins-voxzogo-for-dwarfism-to-face-pressure-from-asce" rel="noreferrer noopener">peptide (CNP) patents</a>.
However, excluding this concern, the company still expects to reach approximately $4 billion in total revenue for fiscal year 2027, driven by growing Voxzogo adoption in the U.S., aided by its broad label without lower age restrictions, which could provide a competitive edge over Ascendis Pharma.
The company is targeting an adjusted operating margin of low-to-mid 40% (starting at 40% in 2026).
The new structure, announced at an investor event,&nbsp;<a target="_blank" href="https://investorday.biomarin.com/static-files/95c517e2-36ee-4427-9278-2d87cc4c1460" rel="noreferrer noopener">covers</a> three key business units: skeletal conditions, enzyme therapies, and Roctavian—its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731810/biomarin-restructures-outlines-roadmap-to-4b-revenues-by-2027" rel="noreferrer noopener">hemophilia A gene therapy</a>.
BioMarin has been implementing a $500 million "cost transformation program"&nbsp;to contribute to non-GAAP operating margin targets set for 2026 and beyond.
Goldman Analyst writes, "We also see external business development as a potential source of upside and diversification beyond BioMarin's guidance. Nonetheless, we note continued investor debate on the outlook given increasing competitive pressure on BioMarin's key growth driver."
The analyst maintains a Buy rating with a <a target="_blank" href="https://www.benzinga.com/quote/BMRN/analyst-ratings" rel="noreferrer noopener">price target of $139</a>.
Price Action: BMRN stock is down 0.57% at $69.09 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41029168/meta-connect-leaks-reveal-affordable-quest-3s-batman-game-bundle-report" target="_blank" rel="noreferrer noopener">Meta Connect Leaks Reveal Affordable Quest 3S, Batman Game Bundle: Report</a>.</li>
</ul>

Analyst Color

Biotech

Health Care

Analyst Ratings

General

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

Financial giants have made a conspicuous bearish move on Biomarin Pharmaceutical. Our analysis of options history for Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $101,040, and 6 were calls, valued at $384,540.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $90.0 for Biomarin Pharmaceutical over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Biomarin Pharmaceutical options trades today is 583.17 with a total volume of 8,431.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Biomarin Pharmaceutical's big money trades within a strike price range of $65.0 to $90.0 over the last 30 days.
<h3>Biomarin Pharmaceutical Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727204455_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.7</td>
<td>$67.50</td>
<td>$114.0K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.6</td>
<td>$4.1</td>
<td>$4.4</td>
<td>$70.00</td>
<td>$88.0K</td>
<td>864</td>
<td>300</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.4</td>
<td>$0.25</td>
<td>$0.35</td>
<td>$90.00</td>
<td>$77.4K</td>
<td>930</td>
<td>3.0K</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.6</td>
<td>$4.4</td>
<td>$4.55</td>
<td>$70.00</td>
<td>$45.1K</td>
<td>864</td>
<td>100</td>
</tr>
<tr>
<td>BMRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$11.6</td>
<td>$11.2</td>
<td>$11.4</td>
<td>$80.00</td>
<td>$41.0K</td>
<td>1.2K</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Biomarin Pharmaceutical</h3>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Current Position of Biomarin Pharmaceutical</h3>
<ul>
<li>Trading volume stands at 1,372,747, with BMRN's price down by -0.2%, positioned at $68.99.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 36 days.</li>
</ul>
<h3>What The Experts Say On Biomarin Pharmaceutical</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $109.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Biomarin Pharmaceutical, targeting a price of $107. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Biomarin Pharmaceutical with a target price of $122. 
&#x2A; An analyst from Bernstein persists with their Outperform rating on Biomarin Pharmaceutical, maintaining a target price of $90. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $110. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Biomarin Pharmaceutical, maintaining a target price of $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biomarin Pharmaceutical with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Biomarin Pharmaceutical Options Trading: A Deep Dive into Market Sentiment

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) has outperformed the market over the past 20 years by 5.46% on an annualized basis producing an average annual return of 13.94%. Currently, Biomarin Pharmaceutical has a market capitalization of $13.44 billion. 
Buying $1000 In BMRN: If an investor had bought $1000 of BMRN stock 20 years ago, it would be worth $13,575.00 today based on a price of $70.59 for BMRN at the time of writing.
<h3>Biomarin Pharmaceutical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727100012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock declined 23.61%. The company announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">at the 2024 ESMO Annual Meeting</a>.</li>
<li>Joint Stock Company Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) stock tumbled 21.66% after Culper Research <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener">issued a short report on the company</a>.</li>
<li>BioMarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) stock lost 16.74% last week <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener">following strong dwarfism drug data</a> from rival Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>).</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) lost 13.26% <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">last week</a>.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) stock fell 11.08% after the company reported worse-than-expected Q1 financial results and <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">cut FY25 guidance</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock decreased 9.01%. Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech received positive CHMP opinion for omicron KP.2-adapted <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener">COVID-19 vaccine in the European Union</a>.</li>
<li>Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) stock fell 7.17%. Several analysts raised <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares declined 6.97% after the company announced a selling stockholder&#8217;s public offering of shares <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">and a concurrent share repurchase</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock fell 6.93% after <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener">headline results from the mid-stage study</a> of monlunabant in obese patients.</li>
<li>Murphy USA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) shares fell 6.90% after JP Morgan downgraded the stock from Neutral to Underweight but raised its <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $415 to $435</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40972008/constellation-energy-li-auto-and-carvana-are-among-top-11-large-cap-gainers-last-week-sept-16-sept" target="_blank" rel="noreferrer noopener">Constellation Energy, Li Auto And Carvana Are Among Top 11 Large Cap Gainers Last Week (Sept 16-Sept 20): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

Highlighting Improvements In Health-Related Quality Of Life, Bone Length, And Strength In Children With Achondroplasia And Other Genetic Skeletal Conditions

BioMarin To Present Positive VOXZOGO (Vosoritide) Data From CANOPY Clinical Program At 2024 International Skeletal Dysplasia Society Meeting

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and lowers the price target from $95 to $78.

Price Target

Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Lowers Price Target to $78

Truist Securities analyst Joon Lee maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Buy and lowers the price target from $118 to $90.

Truist Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $90

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and lowers the price target from $115 to $90.

Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $90

RBC Capital analyst Luca Issi maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and lowers the price target from $100 to $85.

RBC Capital Maintains Sector Perform on Biomarin Pharmaceutical, Lowers Price Target to $85

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Needham cut the price target for Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) from $81 to $78. Needham analyst Gil Blum maintained a Buy rating. Immunocore shares fell 1.6% to close at $33.00 on Monday. <a href="https://www.benzinga.com/quote/IMCR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from $41 to $45. Baird analyst Vikram Kesavabhotla maintained an Outperform rating. Doximity shares rose 0.3% to close at $39.44 on Monday. <a href="https://www.benzinga.com/quote/docs/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) price target from $200 to $300. B of A Securities analyst Andrew Obin upgraded the stock from Neutral to Buy. GE Vernova shares rose 1.9% to close at $229.93 on Monday. <a href="https://www.benzinga.com/quote/gev/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Adecoagro S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) price target from $14.5 to $12.5. Morgan Stanley analyst Javier Martinez downgraded the stock from Overweight to Equal-Weight. Adecoagro shares fell 0.2% to close at $11.55 on Monday. <a href="https://www.benzinga.com/quote/agro/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein slashed the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $174 to $155. Bernstein analyst Richard Clarke maintained an Outperform rating. Airbnb fell 0.2% to close at $117.55 on Monday. <a href="https://www.benzinga.com/quote/abnb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) price target from $230 to $285. Piper Sandler analyst Matt O&#8217;Brien maintained an Overweight rating. Insulet shares rose 0.01% to close at $233.89 on Monday. <a href="https://www.benzinga.com/quote/podd/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) price target from $115 to $87. Stifel analyst Paul Matteis maintained a Buy rating. BioMarin Pharmaceutical shares fell 17.7% to close at $69.86 on Monday. <a href="https://www.benzinga.com/quote/bmrn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen cut the price target for Topgolf Callaway Brands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) from $13 to $10. TD Cowen analyst John Kernan maintained a Hold rating. Topgolf Callaway Brands shares rose 2% to close at $10.40 on Monday. <a href="https://www.benzinga.com/quote/modg/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel slashed Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) price target from $135 to $130. Stifel analyst Matthew Sheerin maintained a Buy rating. Jabil shares fell 0.2% to close at $105.72 on Monday. <a href="https://www.benzinga.com/quote/jbl/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities raised Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) price target from $37 to $41. B. Riley Securities analyst Lucas Pipes maintained a Neutral rating. Alcoa shares rose 6.1% to close at $34.50 on Monday. <a href="https://www.benzinga.com/quote/aa/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="481" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-1024x481.png" alt="" class="wp-image-551787" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-1024x481.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-768x361.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132.png 1322w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40896687/how-to-earn-500-a-month-from-fedex-stock-ahead-of-q1-earnings">How To Earn $500 A Month From FedEx Stock Ahead Of Q1 Earnings</a></li>
</ul>

Pre-Market Outlook

ABNB

AGRO

DOCS

IMCR

MODG

PODD

GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday

B of A Securities analyst Geoff Meacham maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Buy and lowers the price target from $130 to $115.

B of A Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $115

Stifel analyst Paul Matteis maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Buy and lowers the price target from $115 to $87.

Stifel Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $87

Bernstein analyst William Pickering maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform and lowers the price target from $116 to $90.

Bernstein Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $90

Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)&nbsp;released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">disproportionate short stature</a>.
In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth velocity (AGV) superior to placebo.
BioMarin Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) stock is trading lower in reaction to the data <a href="https://www.benzinga.com/general/biotech/22/11/29694519/ascendis-pharmas-program-hits-primary-goal-in-children-with-short-limbed-dwarfism" target="_blank" rel="noreferrer noopener">from rival Ascendis</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40707614/rare-disease-focused-ascendis-pharma-stock-falls-on-underwhelming-q2-earnings-guidance-cut" rel="noreferrer noopener">Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut</a>.
William Blair notes that the efficacy of TransCon CNP is comparable to BioMarin&#8217;s Voxzogo (vosoritide), which is approved for promoting linear growth in children with achondroplasia and open growth plates (epiphyses).
Early data indicates that TransCon CNP could challenge Voxzogo&#8217;s market share by late 2025. Moreover, Ascendis&#8217; TransCon CNP stands out due to its once-weekly dosing schedule and potentially improved safety profile, making it a more appealing option.
The analyst adds, &#8220;We think Ascendis&#8217;s freedom to operate is still unclear given it may be at risk of infringing on BioMarin&#8217;s long-acting CNP patent portfolio, which could restrict Ascendis&#8217; launch or at the very least result in royalties to BioMarin.&#8221;
The William Blair analyst emphasizes BioMarin&#8217;s first-mover advantage, noting that the company is actively conducting additional trials to broaden Voxzogo&#8217;s label.
BioMarin also plans to submit an investigational new drug application for its long-acting CNP in the fourth quarter of 2024. However, competition from TransCon CNP is expected to place continued pressure on Voxzogo&#8217;s market share, which may weigh on the stock in the near future.
Earlier this month, BioMarin&nbsp;announced its&nbsp;plans to land $4 billion in&nbsp;revenue by 2027 and target an adjusted operating margin of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731810/biomarin-restructures-outlines-roadmap-to-4b-revenues-by-2027" rel="noreferrer noopener">low-to-mid 40</a> percent.
Price Action: BMRN stock is down 17.70% at $69.86 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40881407/back-to-back-fda-approvals-for-roches-two-under-the-skin-injections" target="_blank" rel="noreferrer noopener">Back-To-Back FDA Approvals For Roche&#8217;s Two Under-The-Skin Injections</a>.</li>
</ul>

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term

WIIM

BioMarin Pharmaceutical shares are trading lower following strong dwarfism drug data from rival Ascendis.

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Hold and maintains $93 price target.

Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Maintains $93 Price Target

Biomarin Pharmaceutical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NYSE">BMRN</a>) short percent of float has fallen 3.3% since its last report. The company recently reported that it has 6.65 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Biomarin Pharmaceutical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725977718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Biomarin Pharmaceutical has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Biomarin Pharmaceutical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Biomarin Pharmaceutical's peer group average for short interest as a percentage of float is 4.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and maintains $110 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target

Federal regulators are grappling with a significant backlog of factory inspections for drug manufacturing, with many facilities not reviewed since before the pandemic.
An analysis by The Associated Press of FDA data revealed that approximately 42% of the 4,700 registered plants have not undergone FDA surveillance inspections since 2019.
These facilities produce crucial medicines such as antibiotics, blood thinners, and cancer therapies, raising concerns over potential contamination and quality issues.
An AP analysis reveals that approximately 2,000 pharmaceutical manufacturers have not undergone FDA surveillance inspections since before the pandemic. This oversight raises potential contamination risks and other safety issues in medications.
A scholar from Duke University expressed concerns about generic drugmakers reducing costs at the expense of quality, which remains unchecked without proper inspections in an ABC News report.
Tainted medications, like the 2022 incident involving antibiotic-resistant bacteria in eyedrops from an Indian factory, underscore the risks of insufficient oversight.
These factories, particularly in India and China, are critical suppliers of low-cost prescription ingredients in the U.S.
Despite the challenges, FDA Associate Commissioner Michael Rogers <a target="_blank" href="https://abcnews.go.com/Health/wireStory/2000-drug-manufacturing-plants-overdue-fda-inspections-after-113414456" rel="noreferrer noopener">asserted</a> that the FDA is the world&#8217;s most stringent drug regulator. However, he acknowledged that inspection rates are still nearly 40% lower than pre-COVID levels, with no set timeline for clearing the backlog.
The situation is exacerbated by staffing challenges, with many experienced inspectors leaving for more flexible job opportunities.
Internationally, the FDA has been using video and online tools for preliminary assessments, but these do not substitute for physical inspections.
The Government Accountability Office has consistently marked this area as high-risk, signaling that more proactive measures are necessary. In the meantime, the FDA focuses on a risk-based approach to prioritize inspections that pose the greatest public health risk.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40750262/mpox-vaccines-challenges-persist-as-congo-receives-first-batch-of-doses-almost-2-years-after-it-d" target="_blank" rel="noreferrer noopener">Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic</a>.</li>
</ul>
Photo via Shutterstock

Government

Regulations

UTHR

FDA Battles Backlog of Drug Factory Inspections Since COVID-19

BioMarin Pharmaceuticals shares are trading lower after Truist Securities lowered its price target on the stock from $140 to $118.

Analyst Whitney Ijem of Canaccord Genuity maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), retaining the price target ...

Hold Rating on BioMarin Pharmaceutical Amid Competitive Dynamics and Market Penetration Nuances for Voxzogo

Barclays analyst Gena Wang maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $110.00. The...

Barclays Remains a Buy on BioMarin Pharmaceutical (BMRN)

Citi analyst David Lebowitz has maintained their neutral stance on BMRN stock, giving a Hold rating on September 17. David Lebowitz has given his H...

Hold Rating on BioMarin Amid Market Pressures and Steady Therapeutic Leadership

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 9/19/2024, According to Top Analysts

Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers

Wall Street Breakfast: The Week Ahead

BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. BioMarin Pharmaceutical Inc. has reiterated its strong financial outlook initial...

BioMarin Pharmaceutical Projects Strong Growth Through 2034

BioMarin Pharmaceutical reaffirms long-term outlook

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed's recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN), that are poised to skyrocket. Learn more... The biotech industry is experiencing significant growth as it continues to innovate in medicine and life sciences. With rising demand for therapeutics and new treatments targeting several complex diseases such as cancer, Alzheimer's, and rare genetic disorders, the sector is buzzing with potential.
Amid this backdrop, investors looking to gain from this momentum could scoop up the shares of fundamentally sound biotech companies like Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>), BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>), and Royalty Pharma plc (<a href="https://stocknews.com/stock/RPRX/">RPRX</a>) with promising upside potential.
Analysts believe the Federal Reserve's recent rate cuts could further boost the biotech sector. John Maraganore, former CEO of Alnylam Pharmaceuticals, emphasized that the cut "will be very positive for the biotech capital markets," predicting a meaningful uptick in the sector as rates decline. Lower rates mean reduced borrowing costs, allowing biotech firms to raise more capital for their research and development (R&amp;D) projects, potentially accelerating their breakthroughs.
Moreover, the global biotechnology market is anticipated to reach <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion%20in%202024%20and%20is%20expected%20to%20reach%20around%20USD%204.61%20trillion%20by%202034%2C%20expanding%20at%20a%20CAGR%20of%2011.5%25%20from%202024%20to%202034.">$4.61 trillion by 2034</a>, growing at a CAGR of 11.5%. With a focus on next-generation therapies such as gene editing, immunotherapy, and biologics, biotech companies are at the forefront of medical innovation, creating a favorable environment for breakthroughs in life-saving treatments.
With that in mind, let's evaluate the fundamentals of the featured <a href="https://stocknews.com/category/biotech/">Biotech</a> industry stocks, starting with number three:
Stock #3: Royalty Pharma plc (<a href="https://stocknews.com/stock/RPRX/">RPRX</a>)
RPRX operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry. The company's portfolio consists of royalties on nearly 35 commercial products and 14 development-stage product candidates that address therapeutic areas like diabetes, cancer, neuroscience, immunology, respiratory, and hematology.
On September 3, RPRX and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S (<a href="https://stocknews.com/stock/ASND/">ASND</a>), entered into a royalty funding agreement of $150 million based on U.S. net sales of Yorvipath. This transaction supports the continued development and commercialization of Endocrine Rare Disease products.
On May 28, RPRX announced its acquisition of Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million cash. The vorasidenib would be the first targeted therapy for patients with IDH-mutant glioma if approved by the U.S. Food and Drug Administration (FDA).
RPRX for the second quarter (ended June 30, 2024) reported portfolio receipts of $608 million, indicating an 11.6% growth from the prior year quarter. Its operating income increased 8.4% year-over-year to $270 million. In addition, its adjusted EBITDA grew 12.4% from the prior year's quarter to $560 million.
The company's net income and <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> attributable stood at $102 million and $0.23, respectively. Also, the non-GAAP portfolio cash flow came in at $574 million, up 11.2% year-over-year.
The company has updated its fiscal year 2024 financial outlook, increasing its revenue projection to a range of $2.70 billion to $2.78 billion, up from the previous estimate of $2.60 billion to $2.70 billion.
Analysts expect RPRX's revenue for the third quarter (ending September 2024) to grow 39.6% year-over-year to $748.66 million, while its EPS for the same period is expected to increase 16.7% from the prior year to $0.92.
Shares of RPRX have surged 5.2% over the past year to close the last trading session at $27.71. The 12-month median price target of $46.33 indicates <a href="https://www.tipranks.com/stocks/rprx/forecast">a 67.3% upside potential</a> from the last closing price. The price targets range from a low of $38 to a high of $51.
RPRX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
RPRX has a B grade for Growth and Sentiment. It is ranked #33 out of 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/RPRX/">Click here</a> to see the additional ratings for RPRX (Value, Momentum, Stability, and Quality).
Stock #2: BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>)
BMRN develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company is a biotechnology company addressing the root cause of genetic conditions.
On July 24, BMRN announced that the U.S. FDA approved BRINEURA (cerliponase alfa) for children under three years with neuronal ceroid lipofuscinosis type 2 (CLN2 disease). The approval expands the treatment to all ages, including presymptomatic children, to slow the loss of ambulation.
In the fiscal second quarter that ended on June 30, 2024, BMRN's total revenue increased 19.6% year-over-year to $712.03 million. The company reported non-GAAP income from operations of $221.80 million, indicating 71.7% growth from the prior-year quarter. BMRN's non-GAAP net income came in at $188.90 million, up 79.6% year-over-year, while its non-GAAP EPS grew 77.8% from the year-ago value to $0.96.
According to the updated financial guidance for fiscal year 2024, the company's revenue is now projected to be between $2.75 billion and $2.83 billion, with non-GAAP operating margin anticipated to fall between 26% and 27%. Its non-GAAP EPS is expected to range from $3.10 to $3.25.
The consensus revenue estimate of $703.13 million for the fiscal third quarter (ending September 2024) represents a 20.9% increase year-over-year. The consensus EPS estimate of $0.80 for the same quarter indicates a 73.3% improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in three of the trailing four quarters.
The stock has surged marginally intraday to close the last trading session at $69.48. Its 12-month <a href="https://www.tipranks.com/stocks/bmrn/forecast">price target of $105.52</a> reflects a 51.9% potential upside. The price targets range from a low of $72 to a high of $132.
It's no surprise that BMRN has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Growth and a B for Value and Sentiment. Out of 335 stocks in the same industry, BMRN is ranked #14.
Beyond what is stated above, we've also rated BMRN for Momentum, Stability, and Quality. Get all BMRN ratings <a href="https://stocknews.com/stock/BMRN/">here</a>.
Stock #1: Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>)
BIIB is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies worldwide for people with serious and complex diseases. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). 
On August 22, BIIB and Eisai Co., Ltd. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain granted marketing authorization to its Leqembi&#xAE;, the humanized amyloid-beta (Aβ) monoclonal antibody.
On July 30, BIIB, Beckman Coulter, Inc., and Fujirebio announced a collaboration to potentially identify and develop accessible, minimally invasive blood-based biomarkers specific for tau-pathology in the brain. These tools have the potential to be used to stratify patients or monitor treatment response for a new generation of future therapies impacting tau pathology in Alzheimer's disease.
For the second quarter of 2024, which ended on June 30, BIIB's total revenues increased marginally year-over-year to $2.46 billion. Its non-GAAP total net income attributable for the quarter amounted to $770.90 million or $5.28 per share, representing increases of 31.9% and 31.3%, respectively, from the same period last year.
Per the updated financial guidance for the fiscal year 2024, BIIB now forecasts non-GAAP EPS between $15.75 and $16.25, up from the previous estimate of $15 and $16.
Street expects BIIB's revenue for the fiscal fourth quarter (ending December 2024) to increase 2.4% year-over-year to $2.44 billion. Its EPS for the same period is expected to register a 14.7% growth from the prior year, settling at $3.38. In addition, it surpassed the EPS estimates in three of the trailing four quarters, which is promising.
BIIB's stock has declined 0.9% intraday to close the last trading session at $194.12. Its 12-month price target of $274.84 indicates <a href="https://www.tipranks.com/stocks/biib/forecast">a 41.6% potential upside</a>. The price targets range from a low of $190 to a high of $342.
BIIB's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and a B for Growth. Within the Biotech industry, it is ranked #8. <a href="https://stocknews.com/stock/BIIB/">Click here</a> to see BIIB's ratings for Momentum, Stability, Sentiment, and Quality.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
BIIB shares were trading at $190.22 per share on Wednesday afternoon, down $3.90 (-2.01%). Year-to-date, BIIB has declined -26.49%, versus a 21.09% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/biib-rprx-bmrn-asnd-3-biotech-stocks-wall-street-predicts-will-skyrocket/>3 Biotech Stocks Wall Street Predicts Will Skyrocket</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Wall Street Predicts Will Skyrocket

Truist Financial analyst Joon Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) yesterday and set a price target of $...

Truist Financial Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

AERG

ALXO

AZUL

BIIB

BIRK

BRZE

CAGR

COST

CRWD

ETON

GRDN

HUBS

IART

IMRX

INTU

LGCY

LUNR

MPAA

NBIX

NXST

PGHL

RPRX

SFIX

TALO

TURB

VERV

VSTO

ZETA

Press Releases

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy

Earnings

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance

BioMarin to Host 2024 Investor Day on September 4th in New York

BioMarin Announces New R&D and Business Development Leadership

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

AMGEN

KTRA

RHHBY

TSX:RKV

TSXV:RKV

XBIT

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Scotiabank

Truist Securities

Wells Fargo

RBC Capital

B of A Securities

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">2024년 ESMO 연례 회의</a>에서 발표되었다고 발표했다.
2. Joint Stock Company Kaspi.kz(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>)의 주식이 21.66% 급락했다. 이는 컬퍼 리서치(Culper Research)가 <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이 회사에 대한 공매도 보고서를 발표</a>한 후 주가는 21.66% 하락했다.
3. 바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>)의 주식이 16.74% 하락했다. 이는 경쟁사인 아센디스 파마(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)의 <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">강력한 왜소증 치료제 데이터</a> 발표 이후 발생한 일이다.
4. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">지난주</a> 13.26% 하락했다.
5. 페덱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)의 주식은 회사가 예상보다 나쁜 1분기 재무 결과를 보고하고 <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스를 하향 조정</a>한 후 11.08% 하락했다.
6. 바이오엔텍 SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주식이 9.01% 하락했다. 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)와 바이오엔텍은 유럽 연합에서 오미크론(omicron) KP.2 적응 <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">코로나19 백신</a>에 대해 긍정적인 CHMP 의견을 받았다.
7. 아서 J 갤러거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>)의 주식이 7.17% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>한 후 발생한 일이다.
8. 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주식이 6.97% 하락했다. 이는 회사가 주식 공모와 <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">동시 주식 매입</a>을 발표한 후 발생한 일이다.
9. 노보 노디스크 A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 주식은 비만 환자를 대상으로 한 몬루나반트(monlunabant)의 <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중간 단계 연구 결과가 헤드라인</a>을 장식한 후 6.93% 하락했다.
10. 머피 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>)의 주식이 6.90% 하락했다. 이는 JP 모건이 주식 등급을 중립에서 비중축소(Underweight)로 하향 조정했지만 <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 $415에서 $435로 상향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%98%EC%8A%A4%ED%85%94%EB%A0%88%EC%9D%B4%EC%85%98-%EB%B0%8F-%EC%B9%B4%EB%B0%94%EB%82%98%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">콘스텔레이션 및 카바나는 지난주 최고 성과를 보여준 11개 대형주 중 일부 (9월 16일-9월 20일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난주 이들 10개 대형주는 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>나이스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>)의 주가는 회사가 1분기 재무 결과를 보고하고 2분기 조정 매출 지침을 예상치보다 낮은 수준으로 발표한 후 <a href="https://www.benzinga.com//node/38866576" target="_blank" rel="noreferrer noopener">15.60%</a> 하락했다.</li>
<li>페트로브라스 S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>)의 주가는 <a href="https://www.benzinga.com//node/38818917" target="_blank" rel="noreferrer noopener">1분기 매출이 컨센서스</a>를 하회하면서 주가는 13.03% 급락했다. 또한 브라질의 루이스 이나시우 룰라 다시우바 대통령은 <a href="https://www.benzinga.com//node/38850433" target="_blank" rel="noreferrer noopener">배당금</a> 분쟁으로 장 폴 프라테스 CEO를 해고했다.</li>
<li>컴포트 시스템즈 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>)의 주가는 지난주 8.37% 하락했다.</li>
<li>리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주가는 7.64% 하락했는데, 이는 바이든이 <a href="https://www.benzinga.com//node/38813115" target="_blank" rel="noreferrer noopener">중국의 전기차 및 태양광 부문에 관세</a>를 준비하고 있다는 보도에 대한 반응으로 추정된다.</li>
<li>마틴 마리에타 머티리얼스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>)의 주가는 5.23% 하락했다.</li>
<li>벌컨 머티리얼즈 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>)의 주가는 4.89% 떨어졌다.</li>
<li>바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>)의 주가는 170개의 일자리 줄일 계획을 세운 이후 4.47% 하락했다.</li>
<li>뉴 오리엔탈 에듀케이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>)의 <a href="https://www.benzinga.com//node/38866634" target="_blank" rel="noreferrer noopener">주가는 지난주 4.02% 하락했다</a>.</li>
<li>골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주식은 지난주 3.10% 떨어졌다.</li>
<li>미쓰비시 UFJ 파이낸셜 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>)의 주가는 예상보다 나쁜 GDP 데이터 발표 후 2.90% 하락했다.</li>
</ol>
다음 소식: <a href="https://www.benzinga.com/news/24/05/38779404/last-weeks-worst-performing-stocks-are-these-10-large-cap-stocks-in-your-portfolio-may-5-may-11-2024" target="_blank" rel="noopener">지난주 최악의 성과를 낸 주식: 이 10개의 대형주가 귀하의 포트폴리오에 있습니까? (2024년 5월 5일~5월 11일)</a>

Comments

Biomarin Pharmaceutical

뉴스

에 대한 최신 뉴스 Biomarin Pharmaceutical (NASDAQ:BMRN) 주식

월요일, 9월 23, 2024

월요일, 5월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌